Arbuckle Stuart A 4

4 · Praxis Precision Medicines, Inc. · Filed Jun 12, 2026

AI-generated summary of this filing

Updated Jun 12, 2026

Praxis (PRAX) Director Stuart Arbuckle Receives RSU Awards

What Happened

Stuart A. Arbuckle, a director of Praxis Precision Medicines (PRAX), was awarded equity on June 10, 2026: 1,371 restricted stock units (RSUs) and 648 additional share-based awards reported as derivative grants. Both awards were granted at $0.00 (no cash paid) and are compensation awards rather than open-market purchases or sales.

Key Details

Transaction date: 2026-06-10; Form 4 filed: 2026-06-12 (appears timely, within the typical 2-business-day window).
Consideration/price: $0.00 for both awards (standard for compensation grants).
Shares owned after transaction: not specified in the filing.
Footnote highlights:
- F1: The 1,371 RSUs each convert to one share and vest in a single installment on the earlier of June 10, 2027 or the 2027 annual meeting; settlement will be in shares.
- F2: The 648 awards vest in 12 equal monthly installments beginning July 10, 2026, with the final installment on the earlier of June 10, 2027 or the 2027 annual meeting.
Transaction code: "A" (award/grant) — these are compensation awards, not purchases/sales.

Context

These awards are standard director compensation and do not represent an open-market purchase (which some investors view as a stronger bullish signal) nor an immediate sale. The derivative/vesting schedule means value is realized only as awards vest and are settled in shares.

Form 4

Period: 2026-06-10

Director

Transactions

Award
Common Stock
[F1]
2026-06-10+1,371→ 2,537 total
Award
Stock Option (Right to Buy)
[F2]
2026-06-10+648→ 648 total
Exercise: $240.66Exp: 2036-06-10→ Common Stock (648 underlying)

Footnotes (2)

[F1]Mr. Arbuckle was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
[F2]The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.

Signature

/s/ Alex Nemiroff, as Attorney-in-Fact|2026-06-12

1 file